Keresés eredménye

Típusa:
összetett keresés
Keresési paraméterek:
Ahmed Hamed Salem, PhD, FCP | szakcikk |

<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

35 Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Szerző: Constantine S. Tam, MBBS, MD1 Tanya Siddiqi, MD2 John N. Allan, MD3 Thomas J. Kipps, MD, PhD4 Ian W. Flinn, MD, PhD5 Bryone J. Kuss, MBBS, PhD, FRACP, FRCPA6 Stephen Opat, FRACP, FRCPA, MBBS7 Paul M. Barr, MD8 Alessandra Tedeschi, MD9 Ryan Jacobs, MD10 Xavier C. Badoux, MBBS, FRACP, FRCPA11 Paolo Ghia, MD, PhD12 Juthamas Sukbuntherng, PhD13 Ahmed Hamed Salem, PhD, FCP14 Kristin Russell, BS15 Karl Eckert, BA16 Cathy Zhou, MS17 Joi Ninomoto, PharmD18 Danelle F. James, MD, MAS19 William G. Wierda, MD, PhD20
1St. Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
2City of Hope National Medical Center, Duarte, CA
3Weill Cornell Medicine, Long Island City, NY
4UCSD Moores Cancer Center, San Diego, CA
5Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
6Flinders Medical Centre, Bedford Park, Australia
7Monash University, Clayton, VIC, Australia
8Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
9ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
10Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
11Ministry of Health, St George Hospital, Kogarah, Australia
12Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
13Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
14AbbVie, North Chicago, IL
15Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
17Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
19Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
20University of Texas M.D. Anderson Cancer Center, Houston, TX

Background: Ibr is the only once-daily inhibitor of Bruton tyrosine kinase with significant overall survival benefit demonstrated in 2 randomized phase 3 studies in first-line CLL (RESONATE-2; ECOG1912). Both Ibr and Ven, an oral inhibitor of BCL2, are approved in the US for treatment of CLL/SLL. The combination of Ibr + Ven may have synergistic anti-tumor activity given the capacity of Ibr to mobilize CLL cells from protected niches within ...


<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!